Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to […]
More Stories
India and Pakistan Agree to US-Mediated Cease-Fire
By Andrew Thornebrooke India and Pakistan have agreed to the terms of a U.S.-mediated cease-fire following three days of cross-border...
FDA Approves 3 Natural Color Additives Amid Push to Remove Artificial Food Coloring
By Bill Pan The U.S. Food and Drug Administration (FDA) has approved three color additives derived from natural sources for...
Google to Pay $1.4 Billion to Texas, Settle Data Privacy Case
By Naveen Athrappully Google has agreed to settle multiple data privacy lawsuits brought by Texas Attorney General (AG) Ken Paxton...
Ukraine and Allies Call on Russia to Accept US Cease-Fire Proposal
By Andrew Thornebrooke Ukraine and its international partners are calling on Russia to accept a U.S. proposal for a “full,...
Judge Warns Trump’s Order May Violate Previous Ruling on Sanctuary Cities
By Sam Dorman A federal judge has admonished the Trump administration not to use a recent executive order on so-called...
Price T Rowe Associates Inc. MD Has $1.23 Million Holdings in Embecta Corp. (NASDAQ:EMBC)
Price T Rowe Associates Inc. MD raised its stake in Embecta Corp. (NASDAQ:EMBC – Free Report) by 6.8% during the...